NRX Pharmaceuticals Secures Fast Track Designation from FDA for NRX-100, Aiming to Combat Suicidal Depression
Reuters
Aug 15, 2025
NRX Pharmaceuticals Secures <a href="https://laohu8.com/S/FTRK">Fast Track</a> Designation from FDA for NRX-100, Aiming to Combat Suicidal Depression
NRX Pharmaceuticals Inc. has announced that its drug NRX-100, an IV ketamine treatment for suicidality in patients with depression, including bipolar depression, has received Fast Track Designation from the FDA. This designation indicates that NRX-100 has the potential to address an unmet medical need, based on preliminary data. The Fast Track Designation facilitates expedited review processes and enhances communication with the FDA, potentially leading to Priority Review and Rolling Review. NRX Pharmaceuticals plans to submit patient-level data demonstrating the drug's efficacy in reducing suicidal ideation and depression. The company is also seeking eligibility for the Commissioner's National Priority Voucher Program and the FDA's Accelerated Approval Program, which could further expedite the regulatory review of NRX-100.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-027059), on August 15, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.